Total Payments
$364,881
2024 Payments
$4,337
Companies
16
Transactions
82
Medicare Patients
2,291
Medicare Billing
$71,983
Payment Breakdown by Category
Research$360,165 (98.7%)
Travel$2,878 (0.8%)
Food & Beverage$1,175 (0.3%)
Consulting$625.00 (0.2%)
Education$38.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $360,165 | 48 | 98.7% |
| Travel and Lodging | $2,878 | 13 | 0.8% |
| Food and Beverage | $1,175 | 18 | 0.3% |
| Consulting Fee | $625.00 | 2 | 0.2% |
| Education | $38.00 | 1 | 0.0% |
Payments by Type
Research
$360,165
48 transactions
General
$4,716
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celltrion, Inc. | $299,167 | 4 | $0 (2022) |
| PFIZER INC. | $53,515 | 22 | $0 (2023) |
| Bausch Health US, LLC | $2,825 | 1 | $0 (2019) |
| Eli Lilly and Company | $2,016 | 2 | $0 (2018) |
| Lexicon Pharmaceuticals, Inc. | $1,575 | 3 | $0 (2024) |
| ModernaTX, Inc. | $1,476 | 14 | $0 (2024) |
| AbbVie, Inc. | $1,280 | 14 | $0 (2019) |
| Shionogi Inc | $1,159 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,122 | 7 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $300.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,337 | 26 | Lexicon Pharmaceuticals, Inc. ($1,575) |
| 2023 | $54,675 | 25 | PFIZER INC. ($53,515) |
| 2022 | $32,151 | 2 | Celltrion, Inc. ($31,851) |
| 2021 | $252,331 | 2 | Celltrion, Inc. ($252,316) |
| 2020 | $15,000 | 2 | Celltrion, Inc. ($15,000) |
| 2019 | $4,158 | 17 | Bausch Health US, LLC ($2,825) |
| 2018 | $685.32 | 3 | Eli Lilly and Company ($600.00) |
| 2017 | $1,544 | 5 | Eli Lilly and Company ($1,416) |
All Payment Transactions
82 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | AstraZeneca UK Limited | AIRSUPRA (Drug) | Travel and Lodging | Cash or cash equivalent | $114.01 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca UK Limited | AIRSUPRA (Drug) | Food and Beverage | Cash or cash equivalent | $50.98 | General |
| Category: Respiratory | ||||||
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $361.21 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $235.69 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $155.01 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $111.15 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | Cash or cash equivalent | $72.04 | General |
| 09/22/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $14.07 | General |
| 09/21/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $172.53 | General |
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,191.49 | Research |
| Study: LX9211 | ||||||
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $242.06 | Research |
| Study: LX9211 | ||||||
| 04/25/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $141.45 | Research |
| Study: LX9211 | ||||||
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $592.80 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $217.35 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $191.30 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $44.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $32.02 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $27.85 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $23.73 | General |
| 01/04/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $23.73 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CT-P59 3.2 | Celltrion, Inc. | $284,167 | 2 |
| A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | PFIZER INC. | $28,973 | 11 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $15,550 | 3 |
| CT-P17 3.1 | Celltrion, Inc. | $15,000 | 2 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $6,312 | 4 |
| An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation IBS-C | Bausch Health US, LLC | $2,825 | 1 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $2,680 | 4 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-2 STUDY | Eli Lilly and Company | $2,016 | 2 |
| LX9211 | Lexicon Pharmaceuticals, Inc. | $1,575 | 3 |
| M16-009 | AbbVie, Inc. | $758.45 | 6 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $112.45 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 38 | 38 | $6,358 | $812.54 |
| 2022 | 6 | 1,431 | 1,588 | $246,844 | $41,617 |
| 2021 | 4 | 624 | 655 | $78,915 | $19,057 |
| 2020 | 7 | 198 | 348 | $28,549 | $10,496 |
Total Patients
2,291
Total Services
2,629
Medicare Billing
$71,983
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 38 | 38 | $6,358 | $812.54 | 12.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 1,299 | 1,452 | $217,876 | $31,778 | 14.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 44 | 44 | $9,563 | $3,527 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 45 | $9,835 | $2,899 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $4,650 | $1,999 | 43.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 15 | $4,710 | $1,377 | 29.2% |
| 81003 | Automated urinalysis test | Office | 2022 | 15 | 17 | $210.00 | $37.62 | 17.9% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 498 | 517 | $55,748 | $11,153 | 20.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 69 | 69 | $14,010 | $5,291 | 37.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 49 | $8,757 | $2,544 | 29.0% |
| 81002 | Urinalysis, manual test | Office | 2021 | 19 | 20 | $400.00 | $69.60 | 17.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 66 | 81 | $13,446 | $4,875 | 36.3% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 52 | 52 | $10,088 | $3,533 | 35.0% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 15 | 15 | $1,485 | $1,095 | 73.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 13 | $1,404 | $662.98 | 47.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 27 | 33 | $1,584 | $275.09 | 17.4% |
| 81002 | Urinalysis, manual test | Office | 2020 | 12 | 13 | $260.00 | $45.10 | 17.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 13 | 141 | $282.00 | $10.12 | 3.6% |
About Dr. Steve Choi, M.D
Dr. Steve Choi, M.D is a Family Medicine healthcare provider based in Dayton, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1730186370.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steve Choi, M.D has received a total of $364,881 in payments from pharmaceutical and medical device companies, with $4,337 received in 2024. These payments were reported across 82 transactions from 16 companies. The most common payment nature is "" ($360,165).
As a Medicare-enrolled provider, Choi has provided services to 2,291 Medicare beneficiaries, totaling 2,629 services with total Medicare billing of $71,983. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Dayton, OH
- Active Since 06/28/2005
- Last Updated 06/09/2015
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1730186370
Products in Payments
- NURTEC ODT (Drug) $37,965
- ZAVZPRET (Drug) $15,550
- TRULANCE (Drug) $2,825
- AIRSUPRA (Drug) $164.99
- Xofluza (Drug) $67.49
- Prednisolone 25 (Drug) $28.20
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Dayton
Dr. Martin Schear, Md, MD
Family Medicine — Payments: $37,153
Family Medicine $37,153
Dr. Kimbra Joyce, Do, DO
Family Medicine — Payments: $19,274
Family Medicine $19,274
Dr. Kwasi Nenonene, M.d, M.D
Family Medicine — Payments: $16,548
Family Medicine $16,548
Dr. Clem Kirkland, M.d, M.D
Family Medicine — Payments: $15,511
Family Medicine $15,511
Dr. Jeanne Kirkland, M.d, M.D
Family Medicine — Payments: $15,417
Family Medicine $15,417
Dr. Barbara Bennett, D.o, D.O
Family Medicine — Payments: $15,125
Family Medicine $15,125